FULC
Price
$5.69
Change
+$0.32 (+5.96%)
Updated
May 12, 04:59 PM (EDT)
Capitalization
306.6M
86 days until earnings call
OCUL
Price
$7.40
Change
+$0.34 (+4.82%)
Updated
May 12, 04:59 PM (EDT)
Capitalization
1.12B
91 days until earnings call
Ad is loading...

FULC vs OCUL

Header iconFULC vs OCUL Comparison
Open Charts FULC vs OCULBanner chart's image
Fulcrum Therapeutics
Price$5.69
Change+$0.32 (+5.96%)
Volume$5.73K
Capitalization306.6M
Ocular Therapeutix
Price$7.40
Change+$0.34 (+4.82%)
Volume$31.65K
Capitalization1.12B
FULC vs OCUL Comparison Chart
Loading...
FULC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FULC vs. OCUL commentary
May 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FULC is a StrongBuy and OCUL is a Buy.

Ad is loading...
COMPARISON
Comparison
May 13, 2025
Stock price -- (FULC: $5.68 vs. OCUL: $7.39)
Brand notoriety: FULC and OCUL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FULC: 99% vs. OCUL: 76%
Market capitalization -- FULC: $306.6M vs. OCUL: $1.12B
FULC [@Biotechnology] is valued at $306.6M. OCUL’s [@Biotechnology] market capitalization is $1.12B. The market cap for tickers in the [@Biotechnology] industry ranges from $296.96B to $0. The average market capitalization across the [@Biotechnology] industry is $2.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FULC’s FA Score shows that 1 FA rating(s) are green whileOCUL’s FA Score has 0 green FA rating(s).

  • FULC’s FA Score: 1 green, 4 red.
  • OCUL’s FA Score: 0 green, 5 red.
According to our system of comparison, FULC is a better buy in the long-term than OCUL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FULC’s TA Score shows that 6 TA indicator(s) are bullish while OCUL’s TA Score has 4 bullish TA indicator(s).

  • FULC’s TA Score: 6 bullish, 4 bearish.
  • OCUL’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, FULC is a better buy in the short-term than OCUL.

Price Growth

FULC (@Biotechnology) experienced а -0.87% price change this week, while OCUL (@Biotechnology) price change was -4.40% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.48%. For the same industry, the average monthly price growth was +10.12%, and the average quarterly price growth was -9.68%.

Reported Earning Dates

FULC is expected to report earnings on Aug 06, 2025.

OCUL is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (-3.48% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OCUL($1.13B) has a higher market cap than FULC($307M). FULC YTD gains are higher at: 14.255 vs. OCUL (-17.330). FULC has higher annual earnings (EBITDA): -8.94M vs. OCUL (-176.35M). OCUL has more cash in the bank: 350M vs. FULC (227M). FULC has less debt than OCUL: FULC (8.11M) vs OCUL (76.2M). FULC has higher revenues than OCUL: FULC (80M) vs OCUL (59.6M).
FULCOCULFULC / OCUL
Capitalization307M1.13B27%
EBITDA-8.94M-176.35M5%
Gain YTD14.255-17.330-82%
P/E RatioN/AN/A-
Revenue80M59.6M134%
Total Cash227M350M65%
Total Debt8.11M76.2M11%
FUNDAMENTALS RATINGS
FULC vs OCUL: Fundamental Ratings
FULC
OCUL
OUTLOOK RATING
1..100
4214
VALUATION
overvalued / fair valued / undervalued
1..100
26
Undervalued
52
Fair valued
PROFIT vs RISK RATING
1..100
10090
SMR RATING
1..100
8895
PRICE GROWTH RATING
1..100
3559
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FULC's Valuation (26) in the null industry is in the same range as OCUL (52) in the Pharmaceuticals Other industry. This means that FULC’s stock grew similarly to OCUL’s over the last 12 months.

OCUL's Profit vs Risk Rating (90) in the Pharmaceuticals Other industry is in the same range as FULC (100) in the null industry. This means that OCUL’s stock grew similarly to FULC’s over the last 12 months.

FULC's SMR Rating (88) in the null industry is in the same range as OCUL (95) in the Pharmaceuticals Other industry. This means that FULC’s stock grew similarly to OCUL’s over the last 12 months.

FULC's Price Growth Rating (35) in the null industry is in the same range as OCUL (59) in the Pharmaceuticals Other industry. This means that FULC’s stock grew similarly to OCUL’s over the last 12 months.

FULC's P/E Growth Rating (100) in the null industry is in the same range as OCUL (100) in the Pharmaceuticals Other industry. This means that FULC’s stock grew similarly to OCUL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FULCOCUL
RSI
ODDS (%)
Bearish Trend 4 days ago
83%
Bearish Trend 4 days ago
79%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
81%
Momentum
ODDS (%)
Bullish Trend 4 days ago
81%
Bearish Trend 4 days ago
86%
MACD
ODDS (%)
Bullish Trend 4 days ago
77%
Bearish Trend 4 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 4 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
86%
Bullish Trend 4 days ago
87%
Advances
ODDS (%)
Bullish Trend 8 days ago
86%
Bullish Trend 11 days ago
80%
Declines
ODDS (%)
Bearish Trend 6 days ago
86%
Bearish Trend 6 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
79%
Bearish Trend 4 days ago
81%
Aroon
ODDS (%)
Bullish Trend 4 days ago
87%
Bullish Trend 4 days ago
90%
View a ticker or compare two or three
Ad is loading...
FULC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GCIRX15.080.09
+0.60%
Goldman Sachs Intl Eq Insghts R
CRFRX11.140.01
+0.09%
Calvert Focused Value R6
MERDX33.730.02
+0.06%
Meridian Growth Legacy
CMNIX15.22N/A
N/A
Calamos Market Neutral Income I
TRSZX20.11N/A
N/A
T. Rowe Price Mid-Cap Index Z

FULC and

Correlation & Price change

A.I.dvisor indicates that over the last year, FULC has been loosely correlated with SLS. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if FULC jumps, then SLS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FULC
1D Price
Change %
FULC100%
-0.74%
SLS - FULC
48%
Loosely correlated
-7.14%
ANNX - FULC
40%
Loosely correlated
-5.88%
VRDN - FULC
39%
Loosely correlated
-3.05%
NKTX - FULC
36%
Loosely correlated
-1.03%
MLTX - FULC
34%
Loosely correlated
-3.20%
More

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with EYPT. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
-5.23%
EYPT - OCUL
54%
Loosely correlated
-4.75%
BHVN - OCUL
49%
Loosely correlated
-0.05%
DNLI - OCUL
49%
Loosely correlated
-0.42%
XENE - OCUL
49%
Loosely correlated
-1.46%
BEAM - OCUL
48%
Loosely correlated
+0.93%
More